NCT03863223: A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with history of anti-cancer therapy for MBC, with the exception of one prior hormonal regimen or trastuzumab (Herceptin) used before or after surgery

Comments are closed.

Up ↑